0001104659-21-076488.txt : 20210603
0001104659-21-076488.hdr.sgml : 20210603
20210603174030
ACCESSION NUMBER: 0001104659-21-076488
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210602
FILED AS OF DATE: 20210603
DATE AS OF CHANGE: 20210603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oren Dan
CENTRAL INDEX KEY: 0001636701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 21993814
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexcel Pharma Technologies Ltd.
CENTRAL INDEX KEY: 0001720007
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33357
FILM NUMBER: 21993815
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
BUSINESS PHONE: 97246364040
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc.
CENTRAL INDEX KEY: 0001006281
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 650643773
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
BUSINESS PHONE: 201-696-9345
MAIL ADDRESS:
STREET 1: 2 UNIVERSITY PLAZA
STREET 2: SUITE 100
CITY: HACKENSACK
STATE: NJ
ZIP: 07601
FORMER COMPANY:
FORMER CONFORMED NAME: ORTHODONTIX INC
DATE OF NAME CHANGE: 19980422
FORMER COMPANY:
FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP
DATE OF NAME CHANGE: 19960124
4
1
tm2118431-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-02
1
0001006281
Protalix BioTherapeutics, Inc.
PLX
0001720007
Dexcel Pharma Technologies Ltd.
10 HAKIDMA STREET
YOKNEAM
L3
2069200
ISRAEL
0
0
1
0
0001636701
Oren Dan
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
1
0
Common Stock
2021-06-02
4
S
0
61211
2.5576
D
4494820
D
Common Stock
2021-06-03
4
S
0
857506
2.2534
D
3637314
D
Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.
The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
2021-06-03
/s/ Dan Oren
2021-06-03